AMPH

Amphastar Pharmaceuticals delivered results in Q2 that surpassed Wall Street expectations, reflecting continued strength across its diversified product portfolio and new product introductions. Management pointed to robust demand for commercial brands like BAQSIMI and Primatene MIST, as well as the successful launch of ipratropium bromide, as key drivers behind the quarter’s growth. CEO Bill Peters emphasized the company's progress in expanding manufacturing capabilities and advancing its development pipeline, noting, “We observed continued demand across our commercial portfolio and expanded our manufacturing capabilities.” The positive market reaction followed management’s focus on execution despite ongoing pricing dynamics and competitive pressures in select product lines. Is now the time to buy AMPH? Find out in our full research report (it’s free). Revenue: $183.9 million vs analyst estimates of $180.3 million (5.4% year-on-year growth, 2% beat) Adjusted EPS: $0.91 vs analyst estimates of $0.61 (48.3% beat) Operating Margin: 21.6%, down from 24.2% in the same quarter last year Market Capitalization: $849.9 million While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Ekaterina Knyazkova (JPMorgan) asked about future R&D and SG&A spending, and volatility in gross margins. CFO Bill Peters explained that remediation and new product launches would drive costs higher, but gross margins should remain similar to Q2 levels. Yuchen Ding (Jefferies) inquired about the IMS facility’s FDA warning letter and its revenue exposure. CFO Peters clarified that IMS accounts for about a third of sales, with no current plans to halt production, while regulatory remediation continues. Naoki Martin (Piper Sandler) questioned whether business development priorities favored immediately accretive acquisitions or tolerance for late-stage assets. Peters responded that Amphastar prefers accretive or near-term accretive deals, but will consider late-stage assets if strategically aligned. John Gionco (Needham & Company) sought updates on ipratropium bromide’s market share targets and glucagon’s outlook. Peters confirmed strong initial uptake for ipratropium bromide and expects glucagon’s decline to moderate, with no growth anticipated. Melanie (BofA Securities) asked about anticipated margins for the insulin aspart biosimilar. Peters said margins would likely be at or slightly below current corporate levels due to competitive pricing. In upcoming quarters, the StockStory team will monitor (1) execution of IMS facility remediation and any related operational disruptions, (2) progress on pipeline milestones such as regulatory filings and new clinical trial initiations, and (3) continued uptake for newly launched products like ipratropium bromide. Additionally, shifts in pricing dynamics for core brands and the impact of manufacturing investments will be important signposts for Amphastar’s execution. Amphastar Pharmaceuticals currently trades at $20.28, up from $19.81 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free for active Edge members). WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses. But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE. Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.

Image source: The Motley Fool. Thursday, Aug. 6, 2026 at 5:00 p.m. ET Senior Vice President of Corporate Communications - Dan Dischner Executive Vice President of Regulatory Affairs and Clinical Operations - Tony Marrs Chief Financial Officer and Executive Vice President of Finance - William Peters Operator: Greetingsn and welcome to the Amphastar Pharmaceuticals, Inc. Second Quarter Earnings Call. [Operator Instructions] Please note that certain statements made during this call regarding matters that are not historical facts, including but not limited to management's outlook or predictions for future periods, are forward-looking statements. These statements are based solely on information that is now available to us. We encourage you to review the section entitled Forward-Looking Statements in the press release issued today and the presentation on the company's website. Please refer to our SEC filings, which can be found on the company's website and the SEC's website, for a discussion of numerous factors that may impact our future performance. We will also discuss certain non-GAAP measures. Important information on our use of these measures and reconciliations to U.S. GAAP may be found in our earnings release. Please note this conference is being recorded. Our speakers today are Mr. Bill Peters, CFO; Mr. Dan Dischner, Senior Vice President of Corporate Communications; and Mr. Tony Marrs, Executive Vice President of Regulatory Affairs and Clinical Operations. I will now turn the conference over to your host, Mr. Dan Dischner, Senior Vice President of Corporate Communications. Dan, you may begin. Dan Dischner: Thank you, Paul. Good afternoon, everyone, and thank you for joining Amphastar's Second Quarter 2026 Earnings Call. Earlier today, we reported the financial results for the second quarter ended June 30, 2026, which are available on the Investors page of our website. The second quarter was marked by strong execution across each of our strategic growth pillars. We observed continued demand across our commercial portfolio. We expanded our manufacturing capabilities and advanced both our development pipeline and regulatory programs. As a result, we generated improved financial performance during the second quarter. Revenue increased to approximately $184 million, reflecting both sequential and year-over-year growth. Profitability also improved significantly from the first quarter, driven by increased revenue, margin expansion, and enhanced operating performance. Despite a dynamic operating environment, our strategic priorities have remained consistent. We continue to focus on building a diversified pharmaceutical company supported by 3 complementary growth pillars. First, expanding and optimizing our branded and differentiated commercial portfolio. Second, advancing our pipeline of complex generic and biosimilar products. Third, progressing our proprietary development programs that have the potential to create significant long-term value. We believe this diversified business model provides multiple avenues for growth, enhances resilience, and reduces our dependence on any single product, market, or revenue stream. Turning to the first pillar of our growth strategy, expanding and optimizing our branded and differentiated commercial portfolio. We continued to make meaningful progress during the second quarter. Products such as BAQSIMI and Primatene MIST remain central to our long-term strategy and continue to demonstrate strong consumer demand. BAQSIMI remained an important contributor to our business. Total prescriptions increased approximately 17% compared with the second quarter of last year, demonstrating continued growth in patient demand. BAQSIMI's net sales were approximately $45.5 million, a decrease of approximately 3% compared to the prior year quarter. The difference primarily reflects pricing, rebates, and commercial dynamics. Importantly, strong prescription growth continues to reinforce our confidence in the long-term strength of the franchise. In June, we also completed the third contract year following our acquisition of BAQSIMI from Eli Lilly. During the contract year, BAQSIMI generated $178.3 million in net sales, exceeding the $175 million threshold and triggering our first milestone payment to Lilly. Achieving this milestone reflects the continued strength of the franchise and the successful execution of our commercial strategy since acquiring the product. Our focus remains on expanding patient access, supporting continued prescription growth, and managing the business with disciplined commercial execution to maximize long-term value. Primatene MIST continued to demonstrate strong consumer demand during the quarter. Each in-store sales increased compared with both the prior year quarter and the first quarter of 2026, reflecting continued brand strength and market penetration. While reported net sales declined, the decrease was largely attributable to consumer ordering patterns and the timing of shipments associated with pricing discussions with certain retailers. We believe these were temporary channel-related effects rather than a change in consumer demand. Retail performance remained healthy throughout the quarter, reinforcing our confidence in the Primatene MIST franchise and the effectiveness of our marketing investments and commercial execution. At the same time, performance across our broader portfolio reflected the competitive dynamics that are characteristic of the generic pharmaceutical market. glucagon sales declined compared with the prior year as a result of increased competition. We believe this underscores the importance of continuing to diversify our commercial portfolio and advance new products, which can create multiple sources of growth and enhance the resilience of our business over the long term. Furthermore, during the quarter, our manufacturing facility, Armstrong, benefited from the successful launch of our ipratropium bromide product in April. The launch further demonstrates our ability to advance technically complex generic products from development through regulatory approval and into commercial production, reinforcing a core capability that differentiates our platform. Based on early demand and the current competitive landscape, we believe ipratropium bromide represents an attractive long-term opportunity for Amphastar. We continue to invest strategically across our U.S. manufacturing network to strengthen quality and efficiency, expand automation and capacity, and prepare for upcoming pipeline products. As policymakers and consumers place greater emphasis on domestic pharmaceutical manufacturing and supply chain resilience, we believe our U.S.-based manufacturing footprint, combined with our vertically integrated development and commercialization capabilities, represents a meaningful competitive advantage. These investments not only support our current commercial portfolio, but also provide a strong foundation for future product launches and sustainable long-term growth. IMS, one of our subsidiaries, recently received an FDA warning letter related to the FDA inspection conducted in December 2025. Since the inspection, IMS has continued implementing corrective actions. We have responded to the FDA in a timely manner regarding our remediation plan and continue to work closely with the agency to address the items identified in the warning letter. The warning letter does not require IMS to stop manufacturing or distributing its products. While the remediation effort will require additional resources, at this time, we do not currently anticipate a material adverse effect on Amphastar's overall business operations, commercial portfolio, development pipeline, or sales. We remain committed to addressing the FDA's observations thoroughly and sustainably. Quality remains a fundamental responsibility throughout Amphastar, and we will continue strengthening the overall effectiveness of our quality systems. Turning to our third pillar of growth strategy, advancing our development pipeline, we continue to achieve important regulatory and clinical milestones during the second quarter. For our insulin aspart biosimilar and interchangeable program, we continue preparing for potential commercialization in 2027, subject to regulatory approval. We have also made meaningful progress with our proprietary pipeline. During the second quarter, we initiated the phase I clinical program for AMP-101, our epinephrine nasal product. For AMP-109, our targeted oncology program, non-clinical studies are underway. During the quarter, we received constructive feedback from the FDA and are continuing preparation for regulatory interactions in the near future and an anticipated IND submission. Development activities are ongoing for AMP-110, our synthetic human corticotropin program, and AMP-107, our eye drop program for wet age-related macular degeneration and diabetic macular edema, as we look to advance both towards a future IND submission. While these programs remain in early stages of development, we believe they represent meaningful long-term opportunities. Leveraging our scientific, regulatory, and manufacturing capabilities, these programs have the potential to expand our presence into larger proprietary markets and create additional drivers of future growth and value creation. I will now turn the call over to Bill Peters, our CFO and Executive Vice President of Finance, for a more detailed financial review of the second quarter. William Peters: Thank you, Dan, and good afternoon, everyone. In my comments today, I will discuss the second quarter results and then update some of our assumptions for 2026. Revenues for the second quarter increased 5% to $183.9 million from $174.4 million in the previous year's period. Ipratropium Bromide Inhalation, which we launched in April, led to growth with strong sales of $8.4 million. Vaccinia revenues decreased 3% to $45.5 million, compared to $46.7 million in the prior year. An increase in units sold, contributing $6.9 million in sales, was driven by our continued marketing efforts. Lower average selling prices negatively impacted sales by approximately $8.1 million, primarily as a result of higher rebates and higher 340B pharmacy discounts, some of which may have been duplicated. In May, in response to these pricing dynamics we had seen over the past few quarters, we engaged a third party to support data-driven identification, validation, and resolution of potential 340B duplicate discounts, which led to a smaller impact than we saw in the first quarter. Primatene sales were $21 million in the second quarter, down 8% from $22.9 million in the second quarter of last year due to the timing of customer purchases. Epinephrine sales were relatively flat, as weakness in the vial product was offset by increased demand for our pre-filled syringe product. Glucagon sales declined 42% to $11.9 million from $20.6 million due to increased competition. Sales of other products increased 25% to $66.2 million from $53.1 million, primarily due to recently launched products, including iron sucrose, with sales of $3.5 million, and teriparatide, with sales of $4.5 million, which we launched in August 2025 and December 2025, respectively. An increase in albuterol sales of $2.4 million, which we launched in 2024, also contributed to the increase. Additionally, an increase in phytonadione and sodium bicarbonate sales, driven by higher demand resulting from supplier shortages, and an increase in sales of API from our AMP subsidiary, had a positive impact on sales. Cost of revenues increased 3% to $90.4 million from $87.9 million. However, gross margins increased to 51% of revenues in the second quarter of 2026 compared to 50% in the previous year period. The primary drivers of the change were sales of recently launched products with higher margins such as ipratropium bromide, teriparatide, and iron sucrose. This trend was partially offset by a lower average selling price for BAQSIMI, glucagon, and epinephrine multidose vials. Additionally, we had increased manufacturing costs at our Amphastar facility. Selling, distribution, and marketing expenses increased 30% to $13.3 million from $10.2 million, primarily due to an increase in marketing efforts for BAQSIMI and higher freight expenses. General and administrative spending increased 30% to $18.2 million from $14 million, driven by higher legal expenses, salary and personnel-related expenses, as well as expenses related to the implementation of a new ERP system. Research and development expenditures increased 10% to $22.2 million from $20.1 million, primarily due to an increase in clinical trial expense, largely for our insulin pipeline. Our non-operating expense of $1.2 million during the period compares to a non-operating expense of $2.8 million in the prior year period, primarily due to foreign currency fluctuations and mark-to-market adjustments related to our interest rate swap contract during the quarter. Net income decreased slightly to $30.3 million, but increased on a per-share basis to $0.67 in the second quarter from $31 million, or $0.64 per share in the second quarter of 2025. Adjusted net income was relatively flat at $40.8 million, but increased on a per-share basis to $0.91 in the second quarter compared to an adjusted net income of $40.9 million or $0.85 per share in the second quarter of last year. Adjusted earnings excludes amortization, equity compensation, and one-time events. In the second quarter, we had cash flow from operations of approximately $51.3 million. During the quarter, we accelerated our share repurchase program and bought back approximately $45 million worth of shares. Separately, in June, we achieved the first annual BAQSIMI net sales milestone under our asset purchase agreement with Eli Lilly, which triggers a $100 million payment due in the third quarter of 2026. Before I turn the call back over to Dan, I would like to update some of our guidance for 2026. Due to remediation efforts at our IMS facility, we expect expenses there will increase by $2 million to $3 million per quarter for the next several quarters. Capital expenditures will also increase at this facility, but there will be no change to our previously communicated capital expenditure profile as we redirect spending from our Amphastar facility to our IMS facility. We also expect a slight slowing of sales from IMS as we concentrate on addressing corrective actions, thus improving the quality and manufacturing systems. Importantly, even with this revised outlook, we maintain our overall corporate sales guidance of mid-single digit to high single-digit sales growth, reflecting the strength of our broader portfolio. I will now turn the call back over to Dan. Dan Dischner: Thank you, Bill. Looking ahead, our priorities remain clear. We are focused on supporting continued growth across our commercial portfolio, expanding our U.S. manufacturing capabilities, completing the IMS remediation activities, advancing our near-term regulatory programs, and continuing disciplined investment in our proprietary pipeline. We believe the second quarter highlighted the strength and resilience of Amphastar's diversified business model. Faced with a dynamic operating environment, we delivered improved financial performance, generated continued demand across our key commercial brands, and achieved important regulatory and development milestones. These results reflect the benefits of our diversified growth strategy and the balanced foundation we have built across our commercial portfolio, development pipeline, and manufacturing platform. We also believe Amphastar is well-positioned for the evolving pharmaceutical landscape. Our diversified product portfolio, our U.S.-based finished product manufacturing footprint, vertically integrated capabilities, and growing development pipeline provide multiple avenues of growth and support long-term value creation. With that, we will now take your questions. Paul? Operator: [Operator Instructions] Our first question is from Ekaterina Knyazkova with JPMorgan. Ekaterina Knyazkova: First question is just on operating costs. Can you just elaborate a bit on how we should think about spend from here and what both R&D and SG&A could look like over the next several quarters? A related question just on adjusted gross margins. Seems like there's been quite a bit of volatility in that number over the past few quarters. Just what's been driving that, and what's a good baseline to use for gross margins in the second half of the year? William Peters: Yes. There's a couple things driving the decrease in the first quarter. The primary thing was the BAQSIMI double dip counting that we saw there. That had a pretty negative impact. We had some better impacts in the second quarter as we began some procedures to mitigate that and hired an independent party that's going to help reduce that double discount. The second thing in the second quarter was that we had the launch of Ipratropium Bromide HFA, which is a higher margin product, that really helped out a lot. On a going forward basis, I would expect to see the coming quarter similar to this quarter, because remember, we'll have higher BAQSIMI sales next quarter, those higher sales should offset some of the costs that we're expecting at IMS. Additionally, on the G&A and selling expense, I think the second quarter is also a good comp for those. The R&D expense, we do expect that to tick up a little bit as a percentage of sales on a going forward basis. Operator: Our next question is from Dennis Ding with Jefferies. Yuchen Ding: I have 2 questions. Number one, remind us what's going on with the IMS facility that got the warning letter. If I recall, you guys probably responded to it in late July. Remind us the revenue exposure here again from this facility, what are the next steps from the FDA and when, and then would remediation plans require shutting down some of the production lines? That's question number one. And then question number 2, on BAQSIMI's 340B dynamic, I think you said 80% of that pricing pressure can ultimately go away. Can you reiterate that number on the call today, and how much of that 80% was recovered in Q2, and how much is left to recover in Q3? William Peters: Okay. Let me start with the revenue. IMS makes, the sales are probably about a third of our overall corporate sales on a big picture. However, we are still shipping there. We don't expect to stop shipping there. We still are producing at the same rate that we've been. We have taken some quality steps which have slowed down some of the releases, some of the batches right now to make sure that they've gone through an extra quality review, so that's led to a small delay right now for that. I'll turn it over to Tony for some of the other next steps that we have going on there. Tony Marrs: Yes. As you mentioned, we did respond to the warning letter in late July. Essentially the way these are is you have an interaction where you update the FDA on a routine basis, generally every month or two, just to go over your plan and the program. We've hired a third-party independent consultant that has great experience in helping to work with these kind of projects. We'll continue to just work with them and if there are any remediation efforts, we'll work with them and keep the FDA in the loop with that. If there are any shutdowns, as you mentioned, which is definitely a possibility, we'll do those as needed. We routinely do those now. Whether it's a little bit longer or not remains to be depending on what they find during the remediation and during the assessments. We do routinely have those, unlikely at this point. We don't have any expectation that there'll be any of those, again, it sort of remains to be seen based on the assessments. William Peters: And then going back to the last question on BAQSIMI on the 340B. Now we just implemented that consultant, or that firm that helps us with this in May. We only covered 2 months, and I'll say not all of their actions took place right away. When we talked about reducing 80% of the double-dipping on the last call, I'd say that we probably are halfway there at this point. Operator: Our next question is from David Amsellem with Piper Sandler. Naoki Martin: This is Naoki Martin on for David. First, with respect to BD, is your priority acquiring immediately accretive commercial products, or would you accept some development spending for a differentiated late-stage asset? That's number one. Number 2, also with respect to BD, are you willing to establish a new commercial organization in a new vertical or will any potential targets need to leverage existing commercial infrastructure? Thank you. William Peters: Yes. Good question. As far as the development goes, we have been looking at both development programs and things that would be immediately accretive or soon to be accretive, I'll say, things that are very late stage, essentially filed. Right now, because we in-licensed 3 products last year that are early stage, our real focus and what we prefer to look at are things that would be either immediately accretive or accretive to earnings within a year. That's the strong preference. However, we're looking at multiple things, and if we saw the right thing that was an early stage, we'd probably do that. I think the cost structure of those is very different. For example, when we took a look at the 4 products that we in-licensed last year, the upfront cost was $2 million each. Much, much lower than a BAQSIMI or something else that's already on the market. As far as new commercial verticals, we would consider new commercial verticals, but they would probably be in the areas where we have either some kind of planned product, such as the in-license assets that are in oncology, ophthalmology, and immunology. Those are the 3 areas that we would consider new verticals, in addition to the endocrinology where we have BAQSIMI. I don't see us moving outside of those verticals. Dan Dischner: I do. Operator: Our next question is from Serge Belanger with Needham & Company. John Gionco: This is John on for Serge today. Just a couple on your current product portfolio. The first being the generic Atrovent launch that came about in mid-April. I believe you've highlighted previously that you see this product capturing as much as 50% to 80% of the market. Curious what the early stages of the launch have shown thus far and whether you've narrowed that market share goal at this time. Second, on glucagon, you highlighted that it's still seeing some competitive pressures. Although it increased a little bit in the second quarter over the first quarter, I'm curious if you think that this product is now at a stabilization period and could return to growth in the second half of the year. William Peters: Yes. Generic Atrovent, we've got a nice market share, and we are closing in on that goal range that we have put out there, but we're not quite there yet. We're really happy with where we are at this point, and that product launch has gone really well for us. As far as glucagon goes, we saw several new competitors come in over about an 18-month period, including all the way into late last year. Year-over-year, we haven't finished the decline. On a go-forward basis, that rate of decline, we think will diminish. The worst of that decline is over. However, we don't see this as becoming a growth product again. In all likelihood, it's something where we're finding that we think that the portion of the market that's for diagnostic will grow slightly, but the portion that's for the anti-hypoglycemia will continue to decline somewhat. We don't see this as being a growth thing. It's going to decline. The decline is more muted than it's been over the last several quarters. Operator: Our next question is from Jason Gerberry with BofA Securities. Unknown Analyst: This is [ Melanie ] on for Jason. Just on AMP-004, your insulin aspart. Based on current price levels and anticipated concessions, do you see the product gross margin being relative to corporate levels? William Peters: Yes. This is something that we think will probably be at or slightly below the current corporate gross margin levels, given the competition that we see in those today. It is still being something where we have a fairly large sales potential for us. We think sales will be meaningful for us. Operator: Our next question is from Ben Burnett with Wells Fargo. Tianqi Hang: This is Tianqi on for Ben Burnett. Thanks for taking our questions. One question we have is that on the insulin aspart bioavailability study, recently it's shown up as completed on ClinicalTrials.gov. Is this something that you can touch on? What does the data look like? What is the path forward on this? Thank you. William Peters: Okay. Could you please repeat the question again? I think we were having a little hard time understanding. Tianqi Hang: Sorry. William Peters: Which product are you referring to? Tianqi Hang: Yes, sorry, let me repeat again. Yes, it's the insulin aspart bioavailability study showing up recently on clinicaltrials.gov as completed. Is this something that you can touch on? Have you seen the data? What's the path forward in terms of resubmitting, et cetera? William Peters: The question is about the trial. If you had seen on it's a bioequivalent PK type trial, and it's just measuring the AUC between the 2 products, the reference and the other one. I think that's what it is. What I'll say about that product is we're on schedule for that to have our commercial launch of the product next year in 2027. Operator: There are no further questions at this time. I would like to hand the floor back over to management for any closing remarks. Dan Dischner: Thank you, Paul, and thank you all for the questions today. As highlighted in our remarks today, we remain focused on executing our long-term strategy, strengthening our commercial portfolio, advancing our pipeline, and continuing to invest in our U.S. manufacturing capabilities. Thank you for your continued interest in Amphastar. We appreciate your support and look forward to updating you on our progress next quarter. Operator: This concludes today's conference. You may disconnect your lines at this time. Thank you again for your participation. Before you buy stock in Amphastar Pharmaceuticals, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Amphastar Pharmaceuticals wasn’t one of them. The 10 stocks that made the cut are built for long-term growth and could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $400,209!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,375,393!* That performance is why people listen. With a track record of beating the S&P 500 by 4x, Stock Advisor offers a distinct advantage. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built for the long haul. See the 10 stocks » *Stock Advisor returns as of August 13, 2026. This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. The Motley Fool has positions in and recommends Amphastar Pharmaceuticals. The Motley Fool has a disclosure policy. Amphastar (AMPH) Q2 2026 Earnings Call Transcript was originally published by The Motley Fool

Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 5.4% year on year to $183.9 million. Its non-GAAP profit of $0.91 per share was 48.3% above analysts’ consensus estimates. Is now the time to buy AMPH? Find out in our full research report (it’s free). Revenue: $183.9 million vs analyst estimates of $180.3 million (5.4% year-on-year growth, 2% beat) Adjusted EPS: $0.91 vs analyst estimates of $0.61 (48.3% beat) Operating Margin: 21.6%, down from 24.2% in the same quarter last year Market Capitalization: $873.5 million Amphastar Pharmaceuticals delivered results in Q2 that surpassed Wall Street expectations, reflecting continued strength across its diversified product portfolio and new product introductions. Management pointed to robust demand for commercial brands like BAQSIMI and Primatene MIST, as well as the successful launch of ipratropium bromide, as key drivers behind the quarter’s growth. CEO Bill Peters emphasized the company's progress in expanding manufacturing capabilities and advancing its development pipeline, noting, “We observed continued demand across our commercial portfolio and expanded our manufacturing capabilities.” The positive market reaction followed management’s focus on execution despite ongoing pricing dynamics and competitive pressures in select product lines. Looking ahead, Amphastar’s guidance is shaped by ongoing investments in its proprietary product pipeline, further manufacturing expansion, and the remediation of its IMS facility following a recent FDA warning letter. Management highlighted plans to support growth through the commercialization of pipeline candidates and a disciplined approach to spending. CFO Bill Peters stated, “We are focused on supporting continued growth across our commercial portfolio, expanding our U.S. manufacturing capabilities, and advancing our near-term regulatory programs.” The company anticipates stable sales growth and margin performance, while navigating potential cost increases and operational adjustments at IMS. Management attributed Q2’s outperformance to increased prescription volumes in key brands, new product launches, and disciplined portfolio diversification. Investments in manufacturing and regulatory progress also played a substantial role. BAQSIMI prescription growth: While BAQSIMI’s net sales declined due to pricing and rebate pressures, total prescriptions rose 17% year-over-year, highlighting sustained patient demand and reinforcing management’s confidence in this diabetes-related brand’s long-term trajectory. Primatene MIST resilience: Primatene MIST continued to see strong consumer demand and improved in-store sales, with management noting that net sales declines were due to temporary shipment and retailer inventory timing—not underlying market weakness. Ipratropium bromide launch: The recent introduction of this inhalation product highlighted Amphastar’s ability to bring complex generic drugs to market. Management described early demand as robust and sees this as a new, higher-margin revenue stream. IMS facility FDA warning letter: Remediation at the IMS manufacturing site will require additional resources and may temporarily slow sales from the facility, but management does not anticipate a material adverse effect on the overall business. Steps have been taken to address quality concerns and maintain production continuity. Pipeline advancement: Amphastar achieved key milestones in its proprietary and biosimilar pipeline, including initiating Phase I trials for AMP-101 (epinephrine nasal) and progressing towards regulatory submissions for insulin aspart and other candidates in oncology and ophthalmology. Amphastar’s forward outlook is anchored by continued product diversification, manufacturing investments, and the execution of its development pipeline, though cost headwinds and regulatory remediation remain key themes. Manufacturing and remediation costs: The company expects higher operating expenses over the next few quarters, largely from remediation activities at the IMS facility. Management indicated that these costs will be offset by redirection of capital spending from other sites, but investors should expect a moderate impact on operating margins. Pipeline commercialization: Management is focused on advancing late-stage candidates such as the insulin aspart biosimilar, targeting commercialization in 2027. Success here would broaden Amphastar’s market exposure and reduce reliance on existing brands. Portfolio resilience amid competition: While products like glucagon face ongoing competitive pressure, management expects the impact of new launches and stable demand for core brands to support mid- to high-single-digit sales growth. Risks include pricing dynamics and the outcome of regulatory reviews. In upcoming quarters, the StockStory team will monitor (1) execution of IMS facility remediation and any related operational disruptions, (2) progress on pipeline milestones such as regulatory filings and new clinical trial initiations, and (3) continued uptake for newly launched products like ipratropium bromide. Additionally, shifts in pricing dynamics for core brands and the impact of manufacturing investments will be important signposts for Amphastar’s execution. Amphastar Pharmaceuticals currently trades at $21.84, up from $19.81 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free for active Edge members). ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies. Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE. Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.

Amphastar Pharmaceuticals (AMPH) reported $183.9 million in revenue for the quarter ended June 2026, representing a year-over-year increase of 5.4%. EPS of $0.91 for the same period compares to $0.85 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $181.94 million, representing a surprise of +1.08%. The company delivered an EPS surprise of +37.88%, with the consensus EPS estimate being $0.66. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately. Here is how Amphastar performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net revenues- Primatene MIST: $21 million versus $27.45 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -8.2% change. Net revenues- Epinephrine: $15.85 million versus the two-analyst average estimate of $16.53 million. The reported number represents a year-over-year change of -2%. Net revenues- BAQSIMI: $45.5 million compared to the $43.68 million average estimate based on two analysts. The reported number represents a change of -2.5% year over year. Net revenues- Glucagon: $11.91 million versus $8.01 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -42.2% change. Net revenues- Lidocaine: $15.04 million versus the two-analyst average estimate of $12.91 million. The reported number represents a year-over-year change of +0.3%. View all Key Company Metrics for Amphastar here>>> Shares of Amphastar have returned +7.2% over the past month versus the Zacks S&P 500 composite's +3.3% change. The stock currently has a Zacks Rank #5 (Strong Sell), indicating that it could underperform the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amphastar Pharmaceuticals, Inc. (AMPH) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Interested in Amphastar Pharmaceuticals, Inc.? Here are five stocks we like better. Second-quarter revenue rose 5% to $183.9 million, while diluted EPS increased to $0.67 from $0.64. Growth was driven by new launches, particularly ipratropium bromide inhalation, which generated $8.4 million in sales and supported a gross-margin improvement to 51%. BAQSIMI prescriptions increased 17%, but net sales fell 3% to $45.5 million because rebates and 340B discounts pressured pricing. Amphastar also faces a $100 million BAQSIMI milestone payment due in the third quarter of 2026. An FDA warning letter at IMS is slowing some batch releases and is expected to add $2 million to $3 million in quarterly remediation costs, though manufacturing and distribution continue. Management maintained its 2026 outlook for mid-single-digit to high-single-digit sales growth and said its insulin biosimilar program remains on track for a potential 2027 launch. Top 2 Small Cap Healthcare Stocks to Buy Before Rate Cuts Amphastar Pharmaceuticals (NASDAQ:AMPH) reported second-quarter 2026 revenue growth, supported by recently launched products including ipratropium bromide inhalation, while management said it is addressing an FDA warning letter at its IMS subsidiary and continuing investments in its pipeline and U.S. manufacturing operations. Revenue rose 5% year over year to $183.9 million for the quarter ended June 30, from $174.4 million. Net income was $30.3 million, compared with $31 million a year earlier, while diluted earnings per share increased to $0.67 from $0.64. Adjusted net income was essentially unchanged at $40.8 million, though adjusted EPS rose to $0.91 from $0.85. → 3 Drone Stocks That Should Soar After the Summer Slump Promising Small Biotech Amphastar Sees Actionable Pullback “The second quarter was marked by strong execution across each of our strategic growth pillars,” Senior Vice President of Corporate Communications Dan Dischner said. He cited commercial demand, manufacturing expansion, and progress in development and regulatory programs. Ipratropium bromide inhalation, launched in April, generated $8.4 million in second-quarter sales and was the largest contributor to revenue growth, Chief Financial Officer Bill Peters said. Management said the product, a generic version of Atrovent, has gained a “nice market share” and is approaching the company’s previously stated goal of capturing 50% to 80% of the market. → Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth Other products generated $66.2 million in sales, up 25% from $53.1 million a year earlier. The increase reflected recently launched iron sucrose, which contributed $3.5 million, and teriparatide, which added $4.5 million. Increased sales of albuterol, phytonadione, sodium bicarbonate, and active pharmaceutical ingredients from the company’s AMP subsidiary also contributed. Gross margin increased to 51% of revenue from 50% a year earlier. Peters attributed the improvement primarily to higher-margin launches, including ipratropium bromide, teriparatide, and iron sucrose. The benefit was partly offset by lower average selling prices for BAQSIMI, glucagon, and epinephrine multidose vials, as well as increased manufacturing costs at an Amphastar facility. → Jersey Mike's Serves Fresh Gains After IPO Stumble Management expects third-quarter gross margin to be similar to the second quarter. Peters said anticipated higher BAQSIMI sales should help offset added expenses related to IMS remediation efforts. BAQSIMI net sales declined 3% to $45.5 million from $46.7 million in the prior-year quarter, despite a 17% increase in total prescriptions. Peters said higher unit sales added $6.9 million in revenue, but lower average selling prices reduced sales by about $8.1 million, largely because of increased rebates and 340B pharmacy discounts that may have included duplicate discounts. The company hired a third party in May to identify, validate, and resolve potential duplicate 340B discounts. Management said it had achieved roughly half of its previously discussed goal of reducing 80% of the double-discounting issue. In June, Amphastar completed the third contract year following its BAQSIMI acquisition from Eli Lilly. The product generated $178.3 million in net sales during that contract year, exceeding the $175 million threshold required to trigger the first milestone payment. Amphastar said the milestone creates a $100 million payment obligation due in the third quarter of 2026. Primatene MIST sales declined 8% to $21 million, from $22.9 million a year earlier, due to the timing of customer purchases. Dischner said in-store sales increased both sequentially and year over year, and attributed the reported sales decline to ordering patterns and shipment timing connected with discussions with certain retailers. Glucagon sales fell 42% to $11.9 million as competition increased. Management said the pace of decline should moderate but does not expect glucagon to return to growth, citing continued pressure in the anti-hypoglycemia portion of the market. IMS received an FDA warning letter related to an inspection conducted in December 2025. The company said it responded to the agency in late July, has retained an independent consultant, and will provide the FDA with regular updates on its remediation plan. Management said the warning letter does not require IMS to halt manufacturing or product distribution. IMS accounts for roughly one-third of Amphastar’s overall sales, Peters said, and the facility continues to ship and produce products. However, additional quality reviews have slowed some batch releases. Executive Vice President of Regulatory Affairs and Clinical Operations Tony Marrs said potential production shutdowns could occur if warranted by remediation findings, but management does not currently expect such shutdowns. Amphastar expects IMS remediation expenses to rise by $2 million to $3 million per quarter for the next several quarters. Capital spending at IMS will also increase, although the company said its overall capital-expenditure outlook is unchanged because it will redirect spending from its Amphastar facility. The company also anticipates a slight slowdown in IMS sales as it focuses on corrective actions. Despite those factors, management maintained its outlook for mid-single-digit to high-single-digit corporate sales growth in 2026. Research and development expense rose 10% to $22.2 million, primarily due to higher clinical trial spending for Amphastar’s insulin program. The company said its insulin aspart biosimilar and interchangeable program remains on track for potential commercialization in 2027, subject to regulatory approval. Management expects the product’s gross margin to be at or slightly below corporate gross-margin levels given expected competition. The company also initiated a Phase 1 clinical program for AMP-101, an epinephrine nasal product. Nonclinical studies are underway for AMP-109, a targeted oncology program, following what management described as constructive FDA feedback. Amphastar is preparing for further regulatory interactions and an anticipated investigational new drug application submission. Development also continues for AMP-110, a synthetic human corticotropin program, and AMP-107, an eye-drop program for wet age-related macular degeneration and diabetic macular edema. Management said both programs are being advanced toward future IND submissions. During the quarter, Amphastar generated about $51.3 million in operating cash flow and accelerated its share repurchase activity, buying back approximately $45 million of shares. Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company's manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions. Amphastar's portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. The article "Amphastar Pharmaceuticals Q2 Earnings Call Highlights" was originally published by MarketBeat. View MarketBeat's top stocks for August 2026.

Net revenues of $183.9 million for the three months ended June 30, 2026 GAAP net income of $30.3 million, or $0.67 per share, for the second quarter Adjusted non-GAAP net income of $40.8 million, or $0.91 per share, for the second quarter Company to hold a conference call today at 2:00 p.m. Pacific Time RANCHO CUCAMONGA, Calif., Aug. 6, 2026 /PRNewswire/ -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) ("Amphastar" or the "Company"), a biopharmaceutical company focused on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products, today reported results for the three months ended June 30, 2026. "Our second quarter results reflect the continued execution of our long-term strategy to build a more diversified and innovative biopharmaceutical company. While we continued to navigate pricing and competitive dynamics across portions of our portfolio, we successfully achieved key goals including overall revenue growth, expansion of gross margins, meaningful launches of new products, and continued advancement from both our generic and proprietary development pipelines. These results demonstrate the strength of our integrated business model and position us well for long-term sustainable growth," said Dr. Jack Zhang, Amphastar's President and Chief Executive Officer. Second Quarter Results Changes in net revenues as compared to the second quarter of the prior year were primarily driven by: BAQSIMI® sales decreased primarily due to a lower average selling price, as a result of a change in gross-to-net discounts due to changes in chargebacks and rebates and changes to the customer mix, impacting sales of approximately $8.1 million. This decrease was partially offset by an increase in unit volumes, contributing $6.9 million in sales driven by our continued marketing efforts. Primatene MIST® sales decreased due to the timing of customer purchases rather than changes in the underlying consumer demand. In store demand shows continued growth. Epinephrine sales slightly decreased primarily due to a decrease in our epinephrine multi-dose vial product, as a result of increased competition, impacting sales by $2.2 million. This decrease was partially offset by an increase in demand for our epinephrine pre-filled syringe, as a result of other supplier shortages, contributing $1.9 million in sales. Glucagon sales decreased primarily due to a lower average selling price, impacting sales by $7.5 million, as well as a decrease in unit volumes, which impacted sales by $1.2 million, as a result of competition and the continued shift to ready-to-use glucagon products such as BAQSIMI®. Ipratropium bromide sales were $8.4 million following a successful launch in April 2026. Other pharmaceutical product sales increased primarily due to recently launched products including an increase in iron sucrose sales of $3.5 million and teriparatide sales of $4.5 million, which we launched in August 2025 and December 2025, respectively. Albuterol sales increased primarily due to an increase in unit volumes, as we continue to see positive growth since its launch in August 2024. Additionally impacting sales, were an increase in phytonadione and sodium bicarbonate sales, driven by heightened demand, and an increase in API sales from our ANP subsidiary. Changes in the cost of revenues and gross margin were primarily driven by: Recently launched products, including iron sucrose, teriparatide and ipratropium bromide, as well as an increase in sales of phytonadione, all of which are higher-margin products. This was partially offset by: Selling, distribution, and marketing expense increased primarily due to increased freight expense and the increase in marketing efforts for BAQSIMI®. General and administrative expenses increased primarily due to an increase in legal expenses, expenses associated with implementing a new ERP system and salary and personnel-related expenses. Research and development expenses increased due to an increase in clinical trials expense, primarily for our insulin pipeline products, as well as an increase in salary and personnel-related expenses. This increase was partially offset by a decrease in material and supply expenses. The change in non-operating expenses, net, is primarily a result of foreign currency fluctuation, as well as the mark-to-market adjustments relating to our interest rate swap contract during the three months ended June 30, 2026. Cash flow provided by operating activities for the six months ended June 30, 2026, was $99.2 million. Pipeline Information The Company currently has one abbreviated new drug application ("ANDA") and one biosimilar insulin candidate filed with the FDA for products targeting a combined market size exceeding $1.6 billion, along with two biosimilar products in development targeting a market size exceeding $3.5 billion, and three generic products in development targeting a market size of over $1.2 billion. This market information is based on IQVIA data for the 12 months ended June 30, 2026, supplemented by data provided by the branded company for one of the generic targets. The Company is developing multiple proprietary products with injectable, topical and intranasal dosage forms. The Company's proprietary pipeline also includes four recently in-licensed products including three proprietary peptides targeting oncology and ophthalmology indications, and a fully synthetic corticotropin compound designed to address inflammatory and autoimmune conditions. Conference Call Information The Company will hold a conference call to discuss its financial results today, August 6, 2026, at 2:00 p.m. Pacific Time. To access the conference call, dial toll-free (877) 407-0989 or (201) 389-0921 for international callers, ten minutes before the conference. The call can also be accessed on the Investors page on the Company's website at www.amphastar.com. Non-GAAP Financial Measures To supplement its consolidated financial statements, which are prepared and presented in accordance with U.S. generally accepted accounting principles ("GAAP"), the Company is disclosing non-GAAP financial measures when providing financial results. The Company believes that an evaluation of its ongoing operations (and comparisons of its current operations with historical and future operations) would be difficult if the disclosure of its financial results were limited to financial measures prepared only in accordance with GAAP. As a result, the Company is disclosing certain non-GAAP results, including (i) Adjusted non-GAAP net income (loss) and (ii) Adjusted non-GAAP diluted EPS, which generally excludes amortization expense, share-based compensation, impairment charges, certain debt issuance costs, legal settlements, and other one-time events in order to supplement investors' and other readers' understanding and assessment of the Company's financial performance because the Company's management uses these measures internally for forecasting, budgeting, and measuring its operating performance. Whenever the Company uses such non-GAAP measures, it will provide a reconciliation of non-GAAP financial measures to their most directly comparable GAAP financial measures. Investors and other readers are encouraged to review the related GAAP financial measures and the reconciliation of non-GAAP measures to their most directly comparable GAAP measures set forth below and should consider non-GAAP measures only as a supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with GAAP. Market Data This press release contains market data that we obtained from industry sources. These sources do not guarantee the accuracy or completeness of the information. Although we believe that our industry sources are reliable, we do not independently verify the information. The market data may include projections that are based on a number of other projections. While we believe these assumptions to be reasonable and sound as of the date of this press release, actual results may differ from the projections. About Amphastar Pharmaceuticals, Inc. Amphastar is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells active pharmaceutical ingredient, or API products. Most of the Company's finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. More information and resources are available at www.amphastar.com. Amphastar's logo and other trademarks or service marks of Amphastar, including, but not limited to Amphastar®, BAQSIMI®, Primatene MIST®, REXTOVY®, Amphadase®, and Cortrosyn®, are the property of Amphastar. Forward-Looking Statements All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth and our ability to continue to scale, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the impact of our products, including their potential for continued revenue growth, the strategic trajectory of and market for our product pipeline, our long-term strategic vision, our ability to leverage our existing expertise and technology, the impacts of any licensing agreements and ability to commercialize additional therapies, our in-house manufacturing expertise, our ability to deliver high-quality, affordable therapies to patients, our commercial momentum and position in the market. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission ("SEC"), including in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 26, 2026, in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the SEC on May 7, 2026, and our other filings or reports that we may file with the SEC. You can locate these reports through our website at http://ir.amphastar.com and on the SEC's website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change. View original content to download multimedia:https://www.prnewswire.com/news-releases/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-ended-june-30-2026-302845270.html

Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.91 per share, beating the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $0.85 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +37.88%. A quarter ago, it was expected that this specialty pharmaceutical company would post earnings of $0.7 per share when it actually produced earnings of $0.42, delivering a surprise of -40%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Amphastar, which belongs to the Zacks Medical - Generic Drugs industry, posted revenues of $183.9 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 1.08%. This compares to year-ago revenues of $174.41 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Amphastar shares have lost about 24.4% since the beginning of the year versus the S&P 500's gain of 12.8%. While Amphastar has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Amphastar was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #5 (Strong Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.79 on $195.49 million in revenues for the coming quarter and $2.63 on $739.38 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Generic Drugs is currently in the bottom 12% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, Metagenomi Therapeutics (MGX), has yet to report results for the quarter ended June 2026. This genetic medicines company is expected to post quarterly loss of $0.63 per share in its upcoming report, which represents a year-over-year change of -16.7%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Metagenomi Therapeutics' revenues are expected to be $1.25 million, down 85.3% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amphastar Pharmaceuticals, Inc. (AMPH) : Free Stock Analysis Report Metagenomi Therapeutics, Inc. (MGX) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Amphastar Pharmaceuticals (AMPH) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on August 6. On the other hand, if they miss, the stock may move lower. While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise. This specialty pharmaceutical company is expected to post quarterly earnings of $0.66 per share in its upcoming report, which represents a year-over-year change of -22.4%. Revenues are expected to be $181.94 million, up 4.3% from the year-ago quarter. The consensus EPS estimate for the quarter has been revised 21.18% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change. Price, Consensus and EPS Surprise Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only. A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP. Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell). For Amphastar, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -2.27%. On the other hand, the stock currently carries a Zacks Rank of #5. So, this combination makes it difficult to conclusively predict that Amphastar will beat the consensus EPS estimate. While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number. For the last reported quarter, it was expected that Amphastar would post earnings of $0.7 per share when it actually produced earnings of $0.42, delivering a surprise of -40.00%. Over the last four quarters, the company has beaten consensus EPS estimates two times. An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss. That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. Amphastar doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release. Supernus Pharmaceuticals (SUPN), another stock in the Zacks Medical - Generic Drugs industry, is expected to report earnings per share of $0.54 for the quarter ended June 2026. This estimate points to a year-over-year change of -40.7%. Revenues for the quarter are expected to be $205.04 million, up 23.9% from the year-ago quarter. The consensus EPS estimate for Supernus has remained unchanged over the last 30 days. However, a higher Most Accurate Estimate has resulted in an Earnings ESP of +18.52%. This Earnings ESP, combined with its Zacks Rank #3 (Hold), suggests that Supernus will most likely beat the consensus EPS estimate. The company beat consensus EPS estimates in each of the trailing four quarters. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amphastar Pharmaceuticals, Inc. (AMPH) : Free Stock Analysis Report Supernus Pharmaceuticals, Inc. (SUPN) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

RANCHO CUCAMONGA, Calif., July 29, 2026 /PRNewswire/ -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that the Company will release results for its second quarter of 2026 ended June 30, 2026, after the market closes on Thursday, August 6, 2026, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time. To access the conference call, dial toll-free 877-407-0989, for international calls, dial 201-389-0921, ten minutes before the conference. The call can also be accessed on the Investors page on the Company's website www.amphastar.com. The webcast replay of the call will be available on our Company website within 24 hours after the end of the live conference call. About Amphastar Pharmaceuticals, Inc. Amphastar is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells active pharmaceutical ingredient, or API products. Most of the Company's finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. More information and resources are available at www.amphastar.com. Amphastar's logo and other trademarks or service marks of Amphastar, including, but not limited to Amphastar®, BAQSIMI®, Primatene MIST®, REXTOVY®, Amphadase®, and Cortrosyn®, are the property of Amphastar. Forward Looking Statements All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth and our ability to continue to scale, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the impact of our products, including their potential for continued revenue growth, the strategic trajectory of and market for our product pipeline, our long-term strategic vision, our ability to leverage our existing expertise and technology, the impacts of any licensing agreements and ability to commercialize additional therapies, our in-house manufacturing expertise, our ability to deliver high quality, affordable therapies to patients, our commercial momentum and position in the market. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission ("SEC"), including in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 26, 2026, in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the SEC on May 7, 2026, and our other filings or reports that we may file with the SEC. In particular, there can be no guarantee that our sales strategies will be successful, or that we will continue to experience significant sales of BAQSIMI®. You can locate these reports through our website at http://ir.amphastar.com and on the SEC's website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change. View original content to download multimedia:https://www.prnewswire.com/news-releases/amphastar-pharmaceuticals-to-release-second-quarter-earnings-and-hold-conference-call-on-august-6-2026-302837310.html

Amphastar Pharmaceuticals’ first quarter was marked by flat revenue and a significant shortfall in non-GAAP profit compared to analyst expectations, prompting a negative market reaction. Management cited continued pricing pressure, especially in its branded diabetes product BAQSIMI, and increased competition in selected product categories as key drivers behind the results. CFO William Peters acknowledged, “The pricing issue that we've been encountering appears to be potentially the increase of -- there's multiple things going on there. One, there's some increased rebates, but also potentially, we believe some duplicate rebates, which seems to be a 340B pharmacy issue.” Is now the time to buy AMPH? Find out in our full research report (it’s free). Revenue: $171.2 million vs analyst estimates of $173.1 million (flat year on year, 1.1% miss) Adjusted EPS: $0.42 vs analyst expectations of $0.71 (40.5% miss) Adjusted EBITDA: $60.21 million vs analyst estimates of $77.47 million (35.2% margin, 22.3% miss) Operating Margin: 8%, down from 21.9% in the same quarter last year Market Capitalization: $807.8 million While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Serge Belanger (Needham & Company) asked about the duration and nature of BAQSIMI pricing pressures and the impact of exiting certain international markets. CFO William Peters explained that pricing issues stem from increased and potentially duplicate rebates, and that international exits will be gradual, with limited top-line impact. Anthea Li (Jefferies) inquired about timelines and regulatory status for the synthetic corticotropin and insulin aspart biosimilar programs. EVP Tony Marrs confirmed that regulatory meetings have not yet occurred for corticotropin and reaffirmed a 2027 launch target for insulin aspart. Ekaterina Knyazkova (JPMorgan) questioned the commercial potential and ramp for the insulin aspart biosimilar as well as future trends in glucagon sales. Peters indicated that the product represents a significant market opportunity but will require time to ramp depending on interchangeability status, while glucagon sales are expected to decline further but at a slower rate. Naoki Martin (Piper Sandler) asked about potential generic competition for Primatene MIST and revenue expectations for the newly launched ipratropium bromide product. EVP Dan Dischner stated there is no visibility on imminent generics for Primatene MIST and that ipratropium bromide is expected to be a key growth driver in the near term. No further analyst questions were addressed on the call. Looking ahead, our team will be watching (1) the effectiveness of Amphastar’s pricing and rebate management actions for BAQSIMI, (2) the sales trajectory of the newly launched generic ipratropium bromide inhalation product, and (3) regulatory and development progress toward late-stage pipeline launches targeted for 2027. Updates on cost management and competitive responses in core categories will also be important indicators of execution. Amphastar Pharmaceuticals currently trades at $18.32, down from $24.03 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free for active Edge members). ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively. Find out which 5 stocks it's flagging for this month - FREE. Get Our Top 5 Growth Stocks for Free HERE. Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.